Flutiform fluticasone/formoterol regulatory update

SkyePharma said partner Kyorin submitted an NDA to Japan's Ministry of Health, Labor and Welfare (MHLW) for flutiform fluticasone/formoterol to treat bronchial asthma in patients who require combination therapy with inhaled corticosteroids plus inhaled, long-acting adrenergic receptor beta 2 agonists (LABAs). Kyorin has Japanese rights from SkyePharma to the fixed-dose combination of formoterol, a LABA, and fluticasone, an inhaled corticosteroid. ...